Neuvasq Presents Data Showcasing Promising Novel Multispecific Gpr124-Targeting Antibodies for Blood Retina Barrier Restoration at ARVO 2026

Gpr124 represents a promising novel target for improving the integrity and function of the blood-retina barrier (BRB) with the goal of slowing, halting, preventing or even reversing vision lossNeuvasq ...
The Bakersfield Californian

Neuvasq Presents Data Showcasing Promising Novel Multispecific Gpr124-Targeting Antibodies for ...

In the oxygen-induced retinopathy (OIR) model, NVQ401 reduced both neovascularization and avascular areas. Supporting its potential to protect against vascular leakage and abnormal vessel growth and ...

CSL: The Plasma Moat Is Being Rebuilt While The Market Prices The Noise

CSL Limited's Transformation Program targets $500–$550M in annual pre-tax cost reductions by FY28. Read why CSLLY stock is a ...

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural ...
eLife

Defining the Antigenic Topology and Prospective Binding Breadth of Vaccination-induced SARS-CoV-2 Neutralizing Antibodies

This manuscript provides valuable high-resolution structural insights into the interaction between vaccine-elicited antibodies and SARS‑CoV‑2 evolution. The evidence is solid; however, the conclusions ...
The Manila Times

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data …

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued ...

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...
pharmaphorum

UCB buys T-cell therapy biotech Candid for $2bn upfront

Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...
Le Lézard

Spinogenix Receives U.S. FDA Fast Track Designation for Tazbentetol for the Treatment of ALS

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve the lives of patients worldwide, today announced that ...
Pharmabiz

Australia TGA approves Specialised Therapeutics’ Niktimvo for the treatment of chronic graft-versus-host disease

Australia TGA approves Specialised Therapeutics’ Niktimvo for the treatment of chronic graft-versus-host disease: Singapore Tuesday, May 5, 2026, 12:00 Hrs [IST] Independent bio ...
eLife

Selective JAK Inhibition Reveals Paradoxical and Hierarchical Control of interferon-γ-driven Autoimmunity in AIRE Deficiency

These findings are important because they suggest that more selective JAK inhibition, particularly targeting JAK1 or JAK2, can effectively reduce organ pathology and pathogenic IFN-γ-producing immune ...